Intas Pharmaceuticals Limited

Intas Pharmaceuticals Limited, established in 1984 and based in Ahmedabad, Gujarat, is a global leader in the pharmaceutical industry. With over 10,000 product registrations in more than 85 countries worldwide, the company boasts an extensive portfolio spanning various key therapeutic segments, including CNS, cardiovascular, diabetology, gastroenterology, urology, oncology, hematology, immunology, and neurology. In addition, Intas Pharmaceuticals Limited has a diversified range of products, including biosimilars, nutraceuticals, animal health products, and plasma therapy products, catering to the needs of various markets. In 2022, Intas Pharmaceuticals Limited generated revenue of approximately INR 18,500 scores.

One of the company's standout features is its unwavering emphasis on research and development. The company has 17 advanced facilities with global regulatory authority accreditations, making it a pioneer in biosimilars. Some of its notable products include Terifrac (teriparatide), Pegasta (pegylated filgrastim), MabTas (rituximab), and Thymotas (thymoquinone).

Intas Pharmaceuticals Limited is also committed to social responsibility and corporate citizenship. It supports various initiatives in the areas of education, health care, environment, and community development. It has partnered with several NGOs and government agencies to provide quality health care to the underprivileged sections of society. It has also contributed to the fight against COVID-19 by developing plasma therapy products and a patented immuno-booster add-on to standard treatment.

Foundation: 1984

Headquarters: Ahmedabad, Gujarat
Website: https://www.intaspharma.com/